STOK logo

STOKE THERAPEUTICS INC

STOKNASDAQ
🏆 #2138 by market capUS Equity
$170.69▲ $2.75 (+1.61%)
Simulated price
🔔
Track STOK
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 1.6%
7d▲ 484.2%
14d▲ 506.4%
30d▲ 440.0%
ytd▲ 438.3%
1y▲ 590.9%
🏦Market Cap
$1.65B
Small Cap
📈Revenue Growth (YoY)
+404.5%
High Growth
📊Gross Margin
84.7%
High
💵FCF Margin
-654.9%
Thin
⚖️P/S Ratio
59.6x
Expensive
Otter Score
68
Fair

Trading Snapshot

Day Range
$168.20 – $172.27
52-Week Range
$20.32 – $40.22
Volume
$5.10B
Avg Volume
$6.27B
Shares Outstanding
64.5M
Next Earnings
Oct 29, 2026

Fundamentals Snapshot

Annual Revenue
$184M
Last Q Revenue
$9M
P/E Ratio
-7.6
P/S Ratio
59.6x
EPS (TTM)
$-3.15
Dividend Yield
0.00%
Dilution (1yr)
+2.4%

Why Investors Own STOK

  • ✓High-growth profile — revenue up -1.8% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 58% gross margin and 11% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

STOK logo

STOKE THERAPEUTICS INC

STOK
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$184M▲ +404.5% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
100.0%▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$21M▼ −79.7% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$45M▼ −151.6% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
58.4M▲ +2.4% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$81M▼ −$42M YoY
StockOtter · stockotter.space

About STOKE THERAPEUTICS INC

Stoke Therapeutics, Inc. is an emerging biopharmaceutical company dedicated to developing innovative antisense oligonucleotide (ASO) therapies. Its primary focus is to target and address the fundamental causes of severe genetic disorders, particularly within the United States. The company employs its exclusive Targeted Augmentation of Nuclear Gene Output (TANGO) platform to engineer ASOs that precisely enhance protein expression. Stoke's most advanced candidate, STK-001, is currently progressing through Phase I/IIa clinical trials for Dravet syndrome, a severe and debilitating genetic epilepsy. Additionally, STK-002 is in the preclinical development stage for treating autosomal dominant optic atrophy. The company has also established a licensing and collaborative agreement with Acadia Pharmaceuticals Inc. to identify, develop, and market new RNA-based medicines for critical and rare genetic neurodevelopmental conditions impacting the central nervous system. Formerly known as ASOthera Pharmaceuticals, Inc., the company rebranded to Stoke Therapeutics, Inc. in May 2016. Founded in 2014, Stoke Therapeutics, Inc. maintains its headquarters in Bedford, Massachusetts.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
68/100

Analyst Price Target

ⓘ
Average Target
$203.34
▲ +19.1% Upside
High Target$229.34
Low Target$170.92
Based on 21 analysts

Latest News & Updates

🚀
MarketWatch·2h ago

STOKE THERAPEUTICS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Bloomberg·5h ago

Analysts lift STOK price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Barron’s·1d ago

STOKE THERAPEUTICS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.